Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial-Reference-Cited by-同舟云学术

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial

Published:2014-11-21 Issue:7 Volume:22 Page:596-606
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Buti M.¹,Flisiak R.²,Kao J.-H.³,Chuang W.-L.⁴,Streinu-Cercel A.⁵,Tabak F.⁶,Calistru P.⁷,Goeser T.⁸,Rasenack J.⁹,Horban A.¹⁰,Davis G. L.¹¹,Alberti A.¹²,Mazzella G.¹³,Pol S.¹⁴,Orsenigo R.¹⁵,Brass C.¹⁵

Affiliation:

1. Liver Unit; Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III; Barcelona Spain

2. Department of Infectious Diseases and Hepatology; Medical University of Bialystok; Bialystok Poland

3. National Taiwan University Hospital; Taipei Taiwan

4. Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Taiwan

5. Carol Davila University of Medicine and Pharmacy, and National Institute for Infectious Diseases ‘Prof. Dr. Matei Balş’; Bucharest Romania

6. Istanbul University Cerrahpasa Medical School; Istanbul Turkey

7. Centrul de Diagnostic si Tratament Dr. Viktor Babeş; Bucharest Romania

8. Klinik für Gastroenterologie und Hepatologie Universitätsklinik Köln; Köln Germany

9. Universitätsklinik Albert-Ludwigs Universität Freiburg; Freiburg Germany

10. Warsaw Medical University and Hospital of Infectious Disease; Warsaw Poland

11. Baylor University Medical Center; Dallas TX USA

12. Department of Molecular Medicine; University of Padova; Padova Italy

13. Azienda Ospedaliera di Bologna Policl; S. Orsola-Malpighi Hospital; Bologna Italy

14. Hôpital Cochin; Paris France

15. Novartis Pharma AG; Basel Switzerland

Funder

Novartis

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12360/fullpdf

Reference27 articles.

1. World Health Organization Hepatitis C. Fact sheet N°164; April 2014 http://www.who.int/mediacentre/factsheets/fs164/en/

2. Hepatitis C virus therapy update 2013;Casey;Curr Opin Gastroenterol,2013

3. Current and future therapies for hepatitis C virus infection;Laing;N Engl J Med,2013

4. Hepatitis C in the interferon-free era;Streinu-Cercel;Germs,2013

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus;Viruses;2023-04-17

2. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance;PLOS ONE;2021-05-20

3. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice;PLOS ONE;2020-08-07

4. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir;Clinical Infectious Diseases;2020-05-15

5. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH);Expert Opinion on Investigational Drugs;2019-12-23